Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

/p>

"This year continues to be very eventful for DOR," stated Christopher J. Schaber, PhD, President and CEO of DOR. "With our new partnership with Sigma-Tau, we are working diligently towards the initiation of our confirmatory Phase 3 clinical trial of orBec((R)) in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. Once the clinical trial is initiated, we expect to receive a $1 million milestone payment from Sigma-Tau in accordance with our collaboration agreement."

DOR's Recent Highlights:

On August 4, 2009, DOR announced that the Office of Orphan Products Development of the FDA granted Orphan Drug Designation to Oral BDP (beclomethasone 17,21-dipropionate, or orBec(R)) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease.

On July 8, 2009, DOR announced that it received a European patent addressing its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral delivery of drugs.

On July 7, DOR announced the appointment of Christopher P. Schnittker, CPA, as its new Vice President of Administration and Controller.

On June 29, 2009, DOR announced the publication in Bone Marrow Transplantation of orBec(R) clinical pulmonary data by investigators at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

On June 9, 2009, DOR announced that it received European Medicines Evaluation Agency (EMEA) agreement on the design of its confirmatory Phase 3 clinical trial of orBec(R) in acute GI GVHD.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec((R)) (oral beclomethasone dipropionate or
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... IRVINE, CA (PRWEB) , ... August 28, 2015 ... ... leader in Personalized Medicine, presented two studies at the International Spine Intervention ... on July 28th, 2015 through to August 1st, 2015. With a focus on ...
(Date:8/28/2015)... ... , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues ... Images such as the Fonz in a lab coat and Large Marge have been posted ... field. , FireflySci is proud to be the only cuvette manufacturer is the ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... ... and hybridoma productivity. , ... Fort Collins, CO (PRWEB) March 3, 2010 -- InVitria’s launch ... created to improve monoclonal antibody productivity and deliver easier purification of the target ...
... , ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma 2InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 2China Medical Technologies Reports Third Fiscal Quarter Financial Results 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 4China Medical Technologies Reports Third Fiscal Quarter Financial Results 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 6China Medical Technologies Reports Third Fiscal Quarter Financial Results 7China Medical Technologies Reports Third Fiscal Quarter Financial Results 8China Medical Technologies Reports Third Fiscal Quarter Financial Results 9China Medical Technologies Reports Third Fiscal Quarter Financial Results 10China Medical Technologies Reports Third Fiscal Quarter Financial Results 11China Medical Technologies Reports Third Fiscal Quarter Financial Results 12China Medical Technologies Reports Third Fiscal Quarter Financial Results 13China Medical Technologies Reports Third Fiscal Quarter Financial Results 14China Medical Technologies Reports Third Fiscal Quarter Financial Results 15China Medical Technologies Reports Third Fiscal Quarter Financial Results 16China Medical Technologies Reports Third Fiscal Quarter Financial Results 17China Medical Technologies Reports Third Fiscal Quarter Financial Results 18China Medical Technologies Reports Third Fiscal Quarter Financial Results 19China Medical Technologies Reports Third Fiscal Quarter Financial Results 20China Medical Technologies Reports Third Fiscal Quarter Financial Results 21China Medical Technologies Reports Third Fiscal Quarter Financial Results 22Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 2Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease 3
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... led by University of Pennsylvania paleontologists has characterized a new ... species, a plant-eating sauropod named Yongjinglong datangi , roamed ... ago. This sauropod belonged to a group known as Titanosauria, ... ever walk the earth. At roughly 50-60 feet ...
... substantial fraction of the Neanderthal genome persists in modern human ... data from 665 people from Europe and East Asia shows ... in the DNA of this contemporary group, whose genetic information ... research proposes that someone of non-African descent may have inherited ...
... 2014 includes science issues with far-reaching implications for an ... research and energy, according to an article in ... the American Chemical Society. The mid-term elections occurring this ... efforts, already stymied by a bitter partisan atmosphere. ...
Cached Biology News:Dinosaur fossils from China help Penn researchers describe new 'Titan' 2Dinosaur fossils from China help Penn researchers describe new 'Titan' 3Neanderthal lineages excavated from modern human genomes 2Neanderthal lineages excavated from modern human genomes 3
...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... AgarACE Enzyme(a) is a unique agarose-digesting ... quantitative recovery of intact DNA or RNA ... thermostable that low melting point (LMP) agarose ... be equilibrated to the reaction temperature before ...
Biology Products: